



Erratum

To cite this article: (2012) Erratum, Annals of Medicine, 44:8, 854-858, DOI: [10.3109/07853890.2012.734111](https://doi.org/10.3109/07853890.2012.734111)

To link to this article: <https://doi.org/10.3109/07853890.2012.734111>



Published online: 06 Dec 2012.



Submit your article to this journal [↗](#)



Article views: 226



View related articles [↗](#)

Erratum

In the Journal *Annals of Medicine* 44-S1:2–16 for the article “Oxidative Stress, Noxs and Hypertension: Experimental Evidence and Clinical Controversies”, the incorrect references were published. The correct reference list has now been published and can be seen below.

Informa would like to apologize for this error.

References

- Narayan KM, Ali MK, Koplan JP. Global noncommunicable diseases—where worlds meet. *N Engl J Med*. 2010; 363:1196–8.
- Harrison DG, Vinh A, Lob H, Madhur MS. Role of the adaptive immune system in hypertension. *Curr Opin Pharmacol*. 2010;10:203–7.
- Schiffrin EL. T lymphocytes: a role in hypertension? *Curr Opin Nephrol Hypertens*. 2010;19:181–6.
- Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. *Curr Opin Nephrol Hypertens*. 2005;14:125–131.
- Harris DM, Cohn HI, Pesant S, Eckhart AD. GPCR signaling in hypertension: role of GRKs. *Clin Sci (Lond)*. 2008;115:79–89.
- Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. *Nat Clin Pract Nephrol*. 2006;2:582–593.
- Landmesser U, Harrison DG, Drexler H. Oxidant stress—a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. *Eur J Clin Pharmacol*. 2006;62: 13–19.
- Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. *Histochem Cell Biol*. 2004;122:339–352.
- Droge W. Free radicals in the physiological control of cell function. *Physiol Rev*. 2002;82:47–95.
- Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. *J Biol Chem*. 1998;273:15022–15029.
- Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. *Arterioscler Thromb Vasc Biol*. 2000;20:2175–2183.
- Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signaling by angiotensin II and vascular remodelling in hypertension. *Clin Exp Pharmacol Physiol*. 2003;30:860–866.
- Millar TM, Phan V, Tibbles LA. ROS generation in endothelial hypoxia and reoxygenation stimulates MAP kinase signaling and kinase-dependent neutrophil recruitment. *Free Radic Biol Med*. 2007;42:1165–1677.
- Tabet F, Savoia C, Schiffrin EL, Touyz RM. Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. *J Cardiovasc Pharmacol*. 2004;44:200–208.
- Romanowski A, Murray IR, Huston MJ. Effects of hydrogen peroxide on normal and hypertensive rats. *Pharm Acta Helv*. 1960;35:354–357.
- Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NAD(P)H oxidase activation. Contribution to alterations of vasomotor tone. *J Clin Invest*. 1996;97: 1916–1923.
- Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, Etayo JC. Vascular NADH/NAD(P)H oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. *Hypertension*. 2000;35: 1055–1061.
- Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. *Circulation*. 2004;109:1795–801.
- Kagota S, Tada Y, Kubota Y, Nejime N, Yamaguchi Y, Nakamura K, Kunitomo M, Shinozuka K. Peroxynitrite is involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats. *J Cardiovasc Pharmacol*. 2007;50:677–685.
- Klanke B, Cordasic N, Hartner A, Schmieder RE, Veelken R, Hilgers KF. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. *Nephrol Dial Transplant*. 2008;23:3456–3463.
- Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. *Hypertension*. 2002;40:511–515.
- Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, Takai S, Yamanishi K, Miyazaki M, Matsubara H, Yabe-Nishimura C. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. *Circulation*. 2005;112:2677–85.
- Lavi S, Yang EH, Prasad A, Mathew V, Barsness GW, Rihal CS, Lerman LO, Lerman A. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. *Hypertension*. 2008; 51:127–133.
- Cottone S, Mulè G, Guarneri M, Palermo A, Lorito MC, Riccobene R, Arsena R, Vaccaro F, Vadalà A, Nardi E, Cusimano P, Cerasola G. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. *Nephrol Dial Transplant*. 2009;24:497–503.
- Duffy SJ, Gokce N, Holbrook M, Huang A, Frei B, Keaney JF Jr, Vita JA. Treatment of hypertension with ascorbic acid. *Lancet*. 1999;354:2048–9.
- Kurl S, Tuomainen TP, Laukkanen JA, Nyssönen K, Lakka T, Sivenius J, Salonen JT. Plasma vitamin C modifies the association between hypertension and risk of stroke. *Stroke*. 2002;33:1568–1573.

27. Kamgar M, Zaldivar F, Vaziri ND, Pahl MV. Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. *J Natl Med Assoc.* 2009;101:336–44.
28. Touyz RM, Briones AM. Reactive oxygen species and vascular biology: implications in human hypertension. *Hypertens Res.* 2011;34:5–14.
29. Darko D, Dornhorst A, Kelly FJ, Ritter JM, Chowieniczky PJ. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in Type II diabetes. *Clin Sci (Lond).* 2002;103:339–344.
30. Schiffrin EL. Antioxidants in hypertension and cardiovascular disease. *Mol Interv.* 2010;10:354–62.
31. Fridovich I. Superoxide anion radical (O₂⁻), superoxide dismutases, and related matters. *J Biol Chem.* 1997;272:18515–18517.
32. Giustarini D, Dalle-Donne I, Tsikas D, Rossi R. Oxidative stress and human diseases: Origin, link, measurement, mechanisms, and biomarkers. *Crit Rev Clin Lab Sci.* 2009;46:241–81.
33. Nishino T, Okamoto K, Eger BT, Pai EF, Nishino T. Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase. *FEBS J.* 2008;275:3278–3289.
34. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. *Circ Res.* 2002;91:406–413.
35. Adlam D, Bendall JK, De Bono JP, Alp NJ, Khoo J, Nicoli T, Yokoyama M, Kawashima S, Channon KM. Relationships between nitric oxide-mediated endothelial function, eNOS coupling and blood pressure revealed by eNOS-GTP cyclohydrolase 1 double transgenic mice. *Exp Physiol.* 2007;92:119–126.
36. Lambeth JD. NOX enzymes and the biology of reactive oxygen. *Nat Rev Immunol.* 2004;4:181–9.
37. Geiszt M. NAD(P)H oxidases: New kids on the block. *Cardiovasc Res.* 2006;71:289–299.
38. Touyz RM, Briones AM, Sedeek M, Burger D, Montezano AC. NOX Isoforms and Reactive Oxygen Species in Vascular Health. *Mol Interv.* 2011;11:27–35.
39. Bokoch GM, Zhao T. Regulation of the phagocyte NAD(P)H oxidase by Rac GTPase. *Antioxid Redox Signal.* 2006;8:1533–1548.
40. Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE, Mangalat D, Hoch N, Dikalov S, Rudzinski P, Kapelak B, Sadowski J, Harrison DG. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. *J Am Coll Cardiol.* 2008;52:1803–1809.
41. Leto TL, Morand S, Hurt D, Ueyama T. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. *Antioxid Redox Signal.* 2009;11:260.
42. Petry A, Weitnauer M, Görlach A. Receptor activation of NADPH oxidases. *Antioxid Redox Signal.* 2010;13:467.
43. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. *Am J Physiol Regul Integr Comp Physiol.* 2003;285:R277–297.
44. Briones AM, Tabet F, Callera GE, Montezano AC, Yogi A, He Y, Quinn MT, Salaices M, Touyz RM. Differential regulation of Nox1, Nox2 and Nox4 in vascular smooth muscle cells from WKY and SHR. *J Am Soc Hypertens.* 2011;5:137–153.
45. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. *Nat Rev Drug Discov.* 2011;10:453–471.
46. Nisimoto Y, Tsubouchi R, Diebold BA, Qiao S, Ogawa H, Ohara T, Tamura M. Activation of NAD(P)H oxidase 1 in tumour colon epithelial cells. *Biochem J.* 2008;415:57–65.
47. Gianni D, Dermardirossian C, Bokoch GM. Direct interaction between Tks proteins and the N-terminal proline-rich region (PRR) of NoxA1 mediates Nox1-dependent ROS generation. *Eur J Cell Biol.* 2011;90:164–71.
48. Dutta S, Rittinger K. Regulation of NOXO1 activity through reversible interactions with p22 and NOXA1. *PLoS One.* 2010;5:e10478.
49. Fernandes DC, Manoel AHO, Wosniak J, Laurindo FR. Protein disulfide isomerase overexpression in vascular smooth muscle cells induces spontaneous preemptive NAD(P)H oxidase activation nad Nox1 mRNA expression: effects of nitrosothiol exposure. *Arch Biochem Biophys.* 2009;484:197–204.
50. Lee MY, San Martin A, Mehta PK, Dikalova AE, Garrido AM, Datla SR, Lyons E, Krause KH, Banfi B, Lambeth JD, Lassègue B, Griendling KK. Mechanisms of vascular smooth muscle NAD(P)H oxidase 1 (Nox1) contribution to injury-induced neointimal formation. *Arterioscler Thromb Vasc Biol.* 2009;29:480–487.
51. Manea A, Tanase LI, Raicu M, Simionescu M. Transcriptional regulation of NADPH oxidase isoforms Nox1 and Nox4, by nuclear factor-kappaB in human aortic smooth muscle cells. *Biochem. Biophys. Res. Commun.* 2010;396:901–907.
52. Tabet F, Schiffrin EL, Callera GE, He Y, Yao G, Ostman A, Kappert K, Tonks NK, Touyz RM. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. *Circ Res.* 2008;103:149–154.
53. Rathore R, Zheng YM, Niu CF, Liu QH, Korde A, Ho YS, Wang YX. Hypoxia activates NADPH oxidase to increase [ROS]_i and [Ca²⁺]_i through the mitochondrial ROS-PKCepsilon signaling axis in pulmonary artery smooth muscle cells. *Free Radic Biol Med.* 2008;45:1223–31.
54. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. *Circ Res.* 2002;91:406–413.
55. Dikalova AE, Góngora MC, Harrison DG, Lambeth JD, Dikalov S, Griendling KK. Upregulation of Nox1 in vascular smooth muscle leads to impaired endothelium-dependent relaxation via eNOS uncoupling. *Am J Physiol Heart Circ Physiol.* 2010;299:H673–9.
56. Yogi A, Mercure C, Touyz J, Callera GE, Montezano AC, Aranha AB, Tostes RC, Reudelhuber T, Touyz RM. Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. *Hypertension.* 2008;51:500–506.
57. Basset O, Deffert C, Foti M, Bedard K, Jaquet V, Ogier-Denis E, Krause KH. NADPH oxidase 1 deficiency alters caveolin phosphorylation and angiotensin II-receptor localization in vascular smooth muscle. *Antioxid Redox Signal.* 2009;11:2371–84.
58. Niu XL, Madamanchi NR, Vendrov AE, Tchivilev I, Rojas M, Madamanchi C, Brandes RP, Krause KH, Humphries J, Smith A, Burnand KG, Runge MS. Nox activator 1: a potential target for modulation of vascular reactive oxygen species in atherosclerotic arteries. *Circulation.* 2010;121:549–59.
59. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H

- oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. *Circ Res.* 2002;90:1205–1213.
60. Gupte SA, Kaminski PM, George S, Kouznestova L, Olson SC, Mathew R, Hintze TH, Wolin MS. Peroxide generation by p47phox-Src activation of Nox2 has a key role in protein kinase C-induced arterial smooth muscle contraction. *Am J Physiol Heart Circ Physiol.* 2009;296:H1048–1057.
 61. Han W, Li H, Villar VA, Pascua AM, Dajani MI, Wang X, Natarajan A, Quinn MT, Felder RA, Jose PA, Yu P. Lipid rafts keep NADPH oxidase in the inactive state in human renal proximal tubule cells. *Hypertension.* 2008;51:481–485.
 62. Touyz RM, Mercure C, He Y, Javeshghani D, Yao G, Callera GE, Yogi A, Lochard N, Reudelhuber TL. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NAD(P)H oxidase. *Hypertension.* 2005;45:530–537.
 63. Chen H, Song YS, Chan PH. Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion. *J Cereb Blood Flow Metab.* 2009;29:1262–72.
 64. Violi F, Sanguigni V, Carnevale R, Plebani A, Rossi P, Finocchi A, Pignata C, De Mattia D, Martire B, Pietrogrande MC, Martino S, Gambineri E, Soresina AR, Pignatelli P, Martino F, Basili S, Loffredo L. Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. *Circulation.* 2009;120:1616–22.
 65. Loukogeorgakis SP, van den Berg MJ, Sofat R, Nitsch D, Charakida M, Haiyee B, de Groot E, MacAllister RJ, Kuijpers TW, Deanfield JE. Role of NADPH oxidase in endothelial ischemia/reperfusion injury in humans. *Circulation.* 2010;121:2310–6.
 66. Geiszt M, Kopp JB, Várnai P, Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. *Proc Natl Acad Sci U S A.* 2000;97:8010–4.
 67. Sedeek M, Callera G, Montezano A, Gutsol A, Heitz F, Szyndralewicz C, Page P, Kennedy CR, Burns KD, Touyz RM, Hébert RL. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. *Am J Physiol Renal Physiol.* 2010;299:F1348–58.
 68. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griending KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol.* 2004;24:677–83.
 69. Chen K, Kirber MT, Xiao H, Yang Y, Keaney JF Jr. Regulation of ROS signal transduction by NAD(P)H oxidase 4 localization. *J Cell Biol.* 2008;181:1129–1139.
 70. Wu RF, Ma Z, Liu Z, Terada LS. Nox4-derived H₂O₂ mediates endoplasmic reticulum signaling through local Ras activation. *Mol Cell Biol.* 2010;30:3553–68.
 71. Manea A, Tanase LI, Raicu M, Simionescu M. Jak/STAT signaling pathway regulates nox1 and nox4-based NADPH oxidase in human aortic smooth muscle cells. *Arterioscler Thromb Vasc Biol.* 2010;30:105–12.
 72. Ismail, A. Sturrock, P. Wu, B. Cahill, K. Norman, T. Huecksteadt, K. Sanders, T. Kennedy and J. Hoidal. NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor- β 1 and insulin-like growth factor binding protein-3. *Am. J. Physiol. Lung Cell Mol. Physiol.* 2009;296:489–499.
 73. Schröder K, Wandzioch K, Helmcke I, Brandes RP. Nox4 acts as a switch between differentiation and proliferation in preadipocytes. *Arterioscler Thromb Vasc Biol.* 2009;29:239–45.
 74. Zhang M, Brewer AC, Schröder K, Santos CX, Grieve DJ, Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, Brandes RP, Shah AM. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. *Proc Natl Acad Sci U S A.* 2010;107:18121–6.
 75. Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, Anilkumar N, Ouattara A, Cave AC, Walker SJ, Grieve DJ, Charles RL, Eaton P, Brewer AC, Shah AM. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. *Arterioscler Thromb Vasc Biol.* 2011;31:1368–76.
 76. Serrander L, Jaquet V, Bedard K, Plastre O, Hartley O, Arnaudeau S, Demareux N, Schlegel W, Krause KH. NOX5 is expressed at the plasma membrane and generates superoxide in response to protein kinase C activation. *Biochimie.* 2007;89:1159–1167.
 77. Fulton DJ. Nox5 and the regulation of cellular function. *Antioxid Redox Signal.* 2009;11:2443–52.
 78. Jay DB, Papaharalambus CA, Seidel-Rogol B, Dikalova AE, Lassègue B, Griending KK. Nox5 mediates PDGF-induced proliferation in human aortic smooth muscle cells. *Free Radic Biol Med.* 2008;45:329–335.
 79. Montezano AC, Paravicini TM, Chignalia AZ, Yusuf H, Almasri M, He Y, He G, Callera GE, Krause K-H, Lambeth D, Touyz RM. Nicotinamide Adenine Dinucleotide Phosphate Reduced Oxidase 5 (Nox5) regulation by Angiotensin II and Endothelin-1 is Mediated via Calcium/Calmodulin-dependent Pathways in Human Endothelial Cells. *Circ Res.* 2010;106:1363–1373.
 80. Wosniak J Jr, Santos CX, Kowaltowski AJ, Laurindo FR. Cross-talk between mitochondria and NADPH oxidase: effects of mild mitochondrial dysfunction on angiotensin II-mediated increase in Nox isoform expression and activity in vascular smooth muscle cells. *Antioxid Redox Signal.* 2009;11:1265–1269.
 81. Montezano AC, Burger D, Ceravolo GS, Yusuf H, Montero M, Touyz RM. Novel Nox homologues in the vasculature: focusing on Nox4 and Nox5. *Clin Sci (Lond).* 2011;120:131–41.
 82. Gongora MC, Qin Z, Laude K, Kim HW, McCann L, Folz JR, Dikalov S, Fukai T, Harrison DG. Role of extracellular superoxide dismutase in hypertension. *Hypertension.* 2006;48:473–481.
 83. Daiber A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. *Biochim Biophys Acta.* 2010;1797:897–906.
 84. Tajima M, Kurashima Y, Sugiyama K, Ogura T, Sakagami H. The redox state of glutathione regulates the hypoxic induction of HIF-1. *Eur J Pharmacol.* 2009;606:45–49.
 85. Sui H, Wang W, Wang PH, Liu LS. Effect of glutathione peroxidase mimic ebselen (PZ51) on endothelium and vascular structure of stroke-prone spontaneously hypertensive rats. *Blood Press.* 2005;14:366–372.
 86. Welch WJ, Chabrashvili T, Solis G, Chen Y, Gill PS, Aslam S, Wang X, Ji H, Sandberg K, Jose P, Wilcox CS. Role of extracellular superoxide dismutase in the mouse angiotensin slow pressor response. *Hypertension.* 2006;48:934–941.
 87. Godin N, Liu F, Lau GJ, Brezniceanu ML, Chénier I, Filep JG, Ingelfinger JR, Zhang SL, Chan JS. Catalase overexpression prevents hypertension and tubular apoptosis in angiotensinogen transgenic mice. *Kidney Int.* 2010;77:1086–1097.
 88. Collins AR, Lyon CJ, Xia X, Liu JZ, Tangirala RK, Yin F, Boyadjian R, Bikineyeva A, Praticò D, Harrison DG, Hsueh WA. Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. *Circ Res.* 2009;104:e42–54.

89. Feissner RF, Skalska J, Gaum WE, Sheu SS. Crosstalk signaling between mitochondrial Ca^{2+} and ROS. *Front Biosci.* 2009;14:1197–218.
90. Monteiro HP, Arai RJ, Travassos LR. Protein tyrosine phosphorylation and protein tyrosine nitration in redox signaling. *Antioxid Redox Signal.* 2008;10:843–89.
91. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. *Curr Opin Nephrol Hypertens.* 2005;14(2):125–131.
92. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? *Am J Physiol Regul Integr Comp Physiol.* 2005 Oct;289:R913–935.
93. Hirooka Y. Role of reactive oxygen species in brainstem in neural mechanisms of hypertension. *Auton Neurosci.* 2008;142:20–24.
94. Mori T, Cowley AW Jr, Ito S. Molecular mechanisms and therapeutic strategies of chronic renal injury: physiological role of angiotensin II-induced oxidative stress in renal medulla. *J Pharmacol Sci.* 2006;100:2–8.
95. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? *Am J Physiol Regul Integr Comp Physiol.* 2005;289:R913–35.
96. Hayden MR, Whaley-Connell A, Sowers JR. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. *Am J Nephrol.* 2005;25:553–69.
97. Manning RD Jr, Tian N, Meng S. Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. *Am J Nephrol.* 2005;25:311–7.
98. Hisaki R, Fujita H, Saito F, Kushihiro T. Tempol attenuates the development of hypertensive renal injury in Dahl salt-sensitive rats. *Am J Hypertens.* 2005;18:707–13.
99. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. *Am J Physiol Endocrinol Metab.* 2005;288:E353–9.
100. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, Welch WJ, Wilcox CS. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. *Hypertension.* 2002;39:269–74.
101. Nuyt AM. Mechanisms underlying developmental programming of elevated blood pressure and vascular dysfunction: evidence from human studies and experimental animal models. *Clin Sci (Lond).* 2008;114:1–17.
102. Török J. Participation of nitric oxide in different models of experimental hypertension. *Physiol Res.* 2008;57:813–825.
103. Viel EC, Benkirane K, Javeshghani D, Touyz RM, Schiffrin EL. Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. *Am J Physiol Heart Circ Physiol.* 2008;295: H281–288.
104. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers QT, Taylor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK. p22phox mRNA expression and NAD(P) H oxidase activity are increased in aortas from hypertensive rats. *Circ Res.* 1997;80:45–51.
105. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. *Hypertension.* 2002;40:511–515.
106. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, Shah AM. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. *Circ Res.* 2003;93: 802–5.
107. Laude K, Cai H, Fink B, Hoch N, Weber DS, McCann L, Kojda G, Fukui T, Schmidt HH, Dikalov S, Ramasamy S, Gamez G, Griendling KK, Harrison DG. Hemodynamic and biochemical adaptations to vascular smooth muscle overexpression of p22phox in mice. *Am J Physiol Heart Circ Physiol.* 2005;288:H7–12.
108. Virdis A, Neves MF, Amiri F, Touyz RM, Schiffrin EL. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. *J Hypertens.* 2004;22:535–542.
109. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O_2^{2-} and systolic blood pressure in mice. *Circ Res.* 2001;89:408–414.
110. Gavazzi G, Banfi B, Deffert C, Fiette L, Schappi M, Herrmann F, Krause KH. Decreased bloodpressure in NOX1-deficient mice. *FEBS Lett.* 2006;580:497–504.
111. Dikalova A, Clempus R, Lassegue B, Cheng G, McCoy J, Dikalov S, San Martin A, Lyle A, Weber DS, Weiss D, Taylor WR, Schmidt HH, Owens GK, Lambeth JD, Griendling KK. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. *Circulation.* 2005;112:2668–2676.
112. Touyz RM, Mercure C, He Y, Javeshghani D, Yao G, Callera GE, Yogi A, Lochar N, Reudelhuber TL. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. *Hypertension.* 2005;45:530–537.
113. Yogi A, Mercure C, Touyz J, Callera GE, Montezano AC, Aranha AB, Tostes RC, Reudelhuber T, Touyz RM. Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. *Hypertension.* 2008;51:500–506.
114. Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, Goronzy JJ, Weyand CM, Harrison DG, Guzik TJ. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. *Circulation.* 2010; 122:2529–37.
115. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. *Hypertension.* 2011;57:469–76.
116. Yamamoto E, Tamamaki N, Nakamura T, Kataoka K, Tokutomi Y, Dong YF, Fukuda M, Matsuba S, Ogawa H, Kim-Mitsuyama S. Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation. *Stroke.* 2008;39:3049–56.
117. Callera GE, Touyz RM, Teixeira SA, Muscara MN, Carvalho MH, Fortes ZB, Nigro D, Schiffrin EL, Tostes RC. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. *Hypertension.* 2003; 42:811–817.
118. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. *Hypertension.* 2001;38:606–611.
119. Caimi G, Mulé G, Hopps E, Carollo C, Lo Presti R. Nitric oxide metabolites and oxidative stress in mild essential hypertension. *Clin Hemorheol Microcirc.* 2010;46:321–5.
120. Lacy F, Kailasam MT, O'Connor DT, Schmid-Schonbein GW, Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. *Hypertension.* 2000;36:878–884.
121. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. *Hypertension.* 2002;39:777–780.
122. Lacy F, O'Connor DT, Schmid-Schönbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. *J Hypertens.* 1998;16:291–303.

123. Fearheller DL, Park JY, Sturgeon KM, Williamson ST, Diaz KM, Veerabhadrapa P, Brown MD. Racial differences in oxidative stress and inflammation: in vitro and in vivo. *Clin Transl Sci*. 2011;4:32–7.
124. Simic DV, Mimic-Oka J, Pljesa-Ercegovac M, Savic-Radojevic A, Opacic M, Matic D, Ivanovic B, Simic T. Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different degrees of essential hypertension. *J Hum Hypertens*. 2006;20:149–155.
125. Kruger R, Schutte R, Huisman HW, Van Rooyen JM, Malan NT, Fourie CM, Louw R, van der Westhuizen FH, van Deventer CA, Malan L, Schutte AE. Associations between reactive oxygen species, blood pressure and arterial stiffness in black South Africans: the SABPA study. *J Hum Hypertens*. 2011 Jan 27. doi:10.1038/jhh.2010.134.
126. Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. *J Hypertens*. 2001;19:1245–1254.
127. Touyz RM, Yao G, Quinn MT, Pagano PJ, Schiffrin EL. p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. *Arterioscler Thromb Vasc Biol*. 2005;25:512–518.
128. Zalba G, San Jose G, Moreno MU, Fortuno A, Diez J. NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension. *Antioxid Redox Signal*. 2005;7:1327–1336.
129. Moreno MU, Jose GS, Fortuno A, Beloqui O, Diez J, Zalba G. The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. *J Hypertens*. 2006;24:1299–306.
130. Pacher P, Nivorozhkin A, Szabó C. Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol *Pharmacol Rev* 2006;58: 87–114.
131. Saez GT, Tormos C, Giner V, Chaves J, Lozano JV, Iradi A, Redon J. Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension. *Am J Hypertens*. 2004;17:809–816.
132. Mullan BA, Young IS, Fee H, McCance DR. Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. *Hypertension*. 2002;40:804–9.
133. Zureik M, Galan P, Bertrais S, Mennen L, Czernichow S, Blacher J, Ducimetière P, Hercberg S. Effects of long-term daily low-dose supplementation with antioxidant vitamins and minerals on structure and function of large arteries. *Arterioscler Thromb Vasc Biol*. 2004;24: 1485–1491.
134. Caner M, Karter Y, Uzun H, Curgunlu A, Vehid S, Balci H, Ucel R, Güner I, Kutlu A, Yaldiran A, Oztürk E. Oxidative stress in human sustained and white coat hypertension. *Int J Clin Pract*. 2006;60:1565–1571.
135. Hasnain BI, Mooradian AD. Recent trials of antioxidant therapy: what should we be telling our patients? *Cleve Clin J Med*. 2004;71:327–334.
136. McCance DR, Holmes VA, Maresh MJ, Patterson CC, Walker JD, Pearson DW, Young IS; Diabetes and Pre-eclampsia Intervention Trial (DAPIT) Study Group. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. *Lancet*. 2010;376:259–66.
137. Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, Pearson GD, Wapner RJ, Varner MW, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Smith WJ, Saade G, Sorokin Y, Anderson GB; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Vitamins C and E to prevent complications of pregnancy-associated hypertension. *N Engl J Med*. 2010;362:1282–91.
138. Al-Solaiman Y, Jesri A, Zhao Y, Morrow JD, Egan BM. Low-Sodium DASH reduces oxidative stress and improves vascular function in salt-sensitive humans. *J Hum Hypertens*. 2009;23:826–35.
139. Chen S, Ge Y, Si J, Rifai A, Dworkin LD, Gong R. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. *Kidney Int*. 2008;74:1128–1138.
140. Wray DW, Uberoi A, Lawrenson L, Bailey DM, Richardson RS. Oral antioxidants and cardiovascular health in the exercise-trained and untrained elderly: a radically different outcome. *Clin Sci (Lond)*. 2009;116:433–41.
141. Greig D, Alcaïno H, Castro PF, Garcia L, Verdejo HE, Navarro M, López R, Mellado R, Tapia F, Gabrielli LA, Nogerol C, Chiong M, Godoy I, Lavandero S. Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters. *J Heart Lung Transplant*. 2011;30:408–13.
142. Robbins IM, Hemnes AR, Gibbs JS, Christman BW, Howard L, Meehan S, Cabrita I, Gonzalez R, Oyler T, Zhao L, Du RH, Mendes LA, Wilkins MR. Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. *Exp Lung Res*. 2011;37:26–34.
143. Renke M, Tylicki L, Rutkowski P, Larczynski W, Neuwelt A, Aleksandrowicz E, Łysiak-Szydłowska W, Rutkowski B. The effect of N-acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: a placebo-controlled, randomized, cross-over study. *Med Sci Monit*. 2010;16: PI13–8.
144. Oliveira PJ, Goncalves L, Monteiro P, Providencia LA, Moreno AJ. Are the antioxidant properties of carvedilol important for the protection of cardiac mitochondria? *Curr Vasc Pharmacol*. 2005;3:147–158.
145. Fortuño A, Bidegain J, Robador PA, Hermida J, López-Sagaseta J, Beloqui O, Diez J, Zalba G. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. *Hypertension*. 2009;54:744–50.
146. Silva PS, Fontana V, Palei AC, Sertório JT, Biagi C, Tanus-Santos JE. Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers. *Eur J Clin Pharmacol*. 2011;67:365–70.
147. Kukli ska AM, Mroczko B, Musiał WJ, Sawicki R, Kozieradzka A, Usowicz-Szary ska M, Kami ski K, Knapp M, Szmitkowski M. Hypotensive effect of atorvastatin is not related to changes in inflammation and oxidative stress. *Pharmacol Rep*. 2010;62:883–90.
148. Kim JA, Neupane GP, Lee ES, Jeong BS, Park BC, Thapa P. NADPH oxidase inhibitors: a patent review. *Expert Opin Ther Pat*. 2011;21:1147–1158.